Progress Of Alzheimer’s Disease Related Glucose Metabolism Regulating Hormones And A Research Perspective in Nootropics Of Herbal Medicine

Contact: Audrey Hu Whatsapp/hp: 0086 13880143964 Email: audrey.hu@wecistanche.com

Jia-Qi Zhao, Xiao-Qing Li, Yi-Ming Zhang, Mei-tong Guo, Cheng Han, Yang Shen, Qi Zhang, Shi-Feng Chu, Nai-hong Chen, Wen-Bin He

1 Shanxi Key Laboratory of Chinese Medicine Encephalopathy, Shanxi University of Chinese Medicine, Taiyuan, China;

2 Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China.

Highlight

This article reviews the studies that connect the glucose metabolism-regulating hormones to Alzheimer’s disease and suggests the quality of Alzheimer’s patients is improved by regulating glucose metabolism. Because there are substantial epidemiological studies that have established clearly an association between metabolic and neurodegenerative disorders in general, and it has also been found that the pathologic changes of insulin resistance and glucose metabolism disorder in AD are similar to that in diabetes, it is promising to find a new pathway to consider the research strategy on exploring the nootropics candidates rooting in herbal medicine and its formula.

Cistanche herb can prevent and treat Alzheimer’s disease

Abstract

Alzheimer’s disease is one of the neurodegenerative diseases, its pathological mechanisms still remain unclear. There’s evidence that diabetes is associated with Alzheimer’s disease. However, the fundamental cause of diabetes is abnormal glucose metabolism. There may be an inseparable relationship between glucose metabolism-regulating hormones and Alzheimer’s disease. Here, we review the studies that connect the glucose metabolism-regulating hormones to Alzheimer’s disease, and that suggest the quality of Alzheimer’s patients is improved by regulating glucose metabolism.

Keywords: Alzheimer’s disease; Diabetes; Glucose metabolism; Glucose metabolism-regulating hormones

Anti Alzheimer's disease: Cistanche

Glucose metabolism regulation hormone and AD

Insulin

AD and type 2 diabetes (T2DM)are two kinds of the most common disease of an aging society. T2DM is believed to be the cause of its earliest stage from reduced sensitivity of surrounding tissues to circulating insulin, leading to impaired glucose tolerance [6]. That a similar process of intracellular insulin resistance and insufficiency is occurring in the brain region in AD is becoming evident, including in those without systemic diabetes [7].

Insulin is a molecular weight of 6KD protein, secreted by the islet β cells that are stimulated by endogenous or exogenous substances. Insulin had been regarded as a sort of hormone which hardly can pass through the blood-brain barrier and only exists in the peripheral blood. Until the end of the 1970s, first-hand evidence had been put forward that insulin was present in the rat brain by the RIA method, this finding demonstrated that insulin can through the blood-brain barrier arrive at the center, so that can be adjusted by the centers of the glucose metabolic process, In addition, the neuron can synthesize insulin. The insulin receptor (IR) is widely distributed in the central nervous system (CNS), especially in the hippocampus, cortex, and other regions associated with leaming and memory [8]. Since the discovery of insulin and insulin receptors existing in the CNS had been published, more studies have shown that the insulin in the central region activates signaling pathways such as PI3K/Akt. Moreover, nerve cells uptake glucose by insulin's mediation [9] and regulate synaptic plasticity [10] by insulin signaling pathways in CNS.

The insulin signaling pathway is mainly involved:(1)Phosphoinositide3-kinase (PI3K)pathway associated with cell growth and proliferation [11]; (2)mitogen-activated protein kinase (MAPK) pathway regulated cell differentiation [12]. PI3K/Akt plays an essential role in the insulin signaling pathway. Insulin resistance (IR) is insensitive to insulin in the body. The research found that there were abnormal insulin signaling pathways and insulin resistance which occur in AD patients' brains. Insulin also affects AB production and clearance [13]. The main component of Aβ is amyloid precursor protein (APP)hydrolysis. The hydrolysis of the APP was induced by the PI3K/Akt signaling pathway when insulin resistance appeared, which leads to the increase of Aβ and obstruction of the transport of Aβ. Eventually, the senile plaques formed in the brain [14]. Nevertheless, glycogen synthase kinase(GSK)is one of the important PI3K downstream kinases. And its activity can increase tau's aberrant phosphorylation and finally appear NFTs [15]. Amylin

Amylin is a pancreatic β-cell hormone co-released with insulin in response to food intake. It reduces orexis, gastric acid secretion, limits the rate of gastric emptying, and diminishes pancreatic glucagon secretion [16]. It is the third important active hormone in the pancreas and regulates blood sugar balance with insulin. In the pathological state, high levels of blood amylin have inhibitory effects on insulin secreted when hyperglycemia.

There are many similarities between amylin and the composition of Aβ. For instance, they have an analogical secondary structure [17], which binds to the uniform amyloid receptor [18]. Being degraded by the same Insulin-degrading enzyme and interact with each other in complex ways [19].

Emerging suggests emphasizing that amylin impairs cerebrovascular by amyloid deposition in AD patients [20]. Meanwhile, AD patients have a high concentration of amylin expression in the blood. Therefore, there is an intimate connection between amylin and AD, which may be the second amyloid protein in the brain of AD. Furthermore, the fluorescent labeling experiment proves that the amylin was mainly distributed in mature neurons in the brain of mice, with the most distribution in the cortex, followed by the hippocampus and other parts. With the increase of the age of the AD model mice, the expression of amylin in the cortical region is gradually increasing and forming the plaques, which are the common expression with Aβ [21l. In the physiological status, amylin can fall the blood sugar, but long time high blood glucose levels can result in higher levels of amylin, which can pass through the blood-brain barrier and form aggregates to impair neurocyte, eventually leading to a decline in the ability of leaming and memory.

Glucagon-like peptides

Glucagon-like peptides are two types of glucagon-like peptide-1(GLP-1) and glucagon-like peptide-2(GLP-2). The one, GLP-2 is an intestinal-specific growth factor. The other one, GLP-1 is a secreted peptide that acts as a key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric emptying, enhance pancreatic insulin secretion, and suppress pancreatic glucagon secretion. GLP-1 is secreted from L cells of the gastrointestinal mucosa in response to a meal, and the blood-glucose-lowering action [22]. GLP-1 secretion is closely related to the composition of food. Significantly, GLP-1 increased after high-sugar and high-fat diets [23]. It has an important physiological function in the CNS.

GLP-1 receptors are mainly distributed in the hypothalamus, the deutocerebrum, and tritocerebrum. Activating the GLP-1 receptor in these brain regions can control appetite and reduce food intake, which can control appetite and reduce food intake [24].

Adenylate cyclase is activated when GLP-1 binds to the GLP-1 receptor on the surface of theβcell membrane, so that can improve Cyclic Adenosine monophosphate (cAMP) levels, activate the PKA, cAMP-regulated guanine nucleotide exchange factor II (Epac2), thus promoting under glucose-stimulated insulin secretion. Different from the glucose-dependent insulin secretion effect, GLP-1 promotes the proliferation and differentiation of β cells independent of the concentration of glucose, which can be produced in normal blood glucose. GLP-1 receptor downstream multiple signaling pathways are involved in promoting the proliferation, differentiation, and protection of β cells.

GLP-1 not only regulates the blood glucose level of peripheral blood but also acts as a neurotransmitter in the CNS, which plays an important role in cell proliferation, apoptosis, and neurogenesis [25]. Meanwhile, combined with the corresponding receptors, GLP-1 participates in PI3K and MAPK signal pathways, which can activate the downstream substrate molecule of PKA, promote neurotransmitter release, and improve synaptic plasticity[26]. At the same time, it not just compensates the insulin signal, more improves the insulin resistance phenomenon of AD patients. The experiment found that GLP-1 analogs had an improved effect on the memory which injected Aβ [27], and decreased the formation of Aβ [28].

Benefit of cistanche product: Anti Alzheimer's disease

Asprosin

Asprosin is cut down at the end of the myofibril protein-1, which contains 140 amino acids segment. It can promote the decomposition of liver glucose by the G protein in-cAMP-PKA pathway, and facilitate the absorption of glucose into the cells to keep blood levels at optimum levels [29]. Previous studies manifested that neonatal progeroid syndrome (NPS) patients existed insulin resistance [30]. From the previous review, we can catch that AD has a significant relationship with insulin resistance.

The researchers detected that the diabetic mice model exerts a higher level than a normal cycle of Asprosin, then it was injected a deactivation of the monoclonal antibody to combination with Asprosin, which can regulate the insulin level. If insisting on treatment, the insulin resistance returned to normal [31]. Improving insulin resistance plays a vital role in reducing the incidence of AD.

Glucocorticoids

Glucocorticoids(GC) were secreted by the adrenal cortex zonafasciculata. In humans, cortisol is the main factor, whereas, in rodents, it is mainly corticosterone. It has the function of regulating the metabolism of glycolipid and protein, and also inhibiting immune response, anti-inflammatory and anti-shock. The release of the is regulated glucocorticoid hypothalamic-pituitary-adrenocortical axis (HPA) [32]. A central feature of the stress response is activating the HPA and stimulating the adrenal cortex to release glucocorticoids.

GC is a steroid hormone that passes through the blood-brain barrier to combine with receptors. Glucocorticoid has two receptors in the brain, one is mineralocorticoid receptors (MR) with high affinity, and the other is glucocorticoid receptor(GR) with low affinity, These receptors are expressed mainly in the hippocampus area, where GR was expressed in the CAl region [33]. Temporary high levels of GC can enhance memory, whereas persistent high levels of GC make the GR active so continuously, that can damage the body's memory function [34].

Studies show that cortisol levels in the plasma, saliva, or cerebrospinal fluid of AD patients are higher than those in normal people. The changes in cortisol levels are positively correlated with the memory storage of AD, but the mechanism is unclear [35]. The hippocampus is the advanced center of HPA axis regulation. When the hippocampal lesions in AD patients, the function of the HPA axis is disturbed, while the GC level is elevated. This causes the dendrites of hippocampal neurons to atrophy, lose, regenerate, and eventually, cognitive decline occurs. At the same time, the high level of GC makes the APP hydrolyze faster, and increases the accumulation of Aβlarger. Conversely, the deposition of Aβ is likely to increase the level of GC, form an Aβ vicious circle, and aggravate the condition of AD. The high concentration of GC in the brain stimulates the activation of GSK3 kinase and increases the abnormal phosphorylation of tau protein [36].

medicinal herb:Cistanche

A Research Perspective in Nootropics of Herbal Medicine

As mentioned above, abnormal glucose metabolism and its related hormone have close bonds with the occurrence and development of AD. Although the main theories of AD pathogenesis have been proposed, which are the cholinergic hypothesis and beta-amyloid cascade hypothesis, the mechanism still needs to be elucidated. Clinically, the drugs to treat AD mainly include the anti-cholinesterase drug donepezil, lith's amine, galanthamine, and glutamate receptor antagonist memantine. However, AD still cannot be effectively prevented or cured. Meanwhile, these medications have many side effects besides the length of therapy. Emerged evidence indicate that the intervention of herbal medicines has the characteristics of small side effect and high safety, which makes it possess certain advantages in the treatment of AD.

One of the herbal medicine research groups found in their previous research that curcumin reduced Aβ aggregation in the AD mouse brain, and improved the symptoms of memory impairment. Furtherly, they used immunohistochemistry and western blot techniques to detect the glucose metabolism and insulin pathway in the APP transgenic mice. The results showed that curcumin ameliorated the deficiency of the insulin signaling pathway and improved spatial learning and memory ability by up-regulating the expression of insulin-like growth factor protein[37]. Durairajan et al. suggested that berberine inhibited amyloid precursor protein phosphorylation to prevent Aβ deposition [38]. A study has shown that DanHong Injection can improve the memory ability of diabetic patients [39]. In a clinical trial, taking DanShenDiWan can reduce Aβ deposition and enhance cognitive function in diabetic patients [40]. ZhengSunetal has found that the ZiBuPiIYin recipe can prevent brain damage in diabetic rats. The mechanisms may be affiliated with improving aberrant mitochondrial function, insulin resistance, and reducing A lesion [41]. Chinese medicine is based on the collection of complex interactions, in other words, more research is needed on the synergistic effects of herbal combinations to better understand the mechanisms for disease [42].

A substantial epidemiological study has established clearly an association between metabolic and neurodegenerative disorders in general [43]. It has also been found that the pathologic changes of insulin resistance and glucose metabolism disorder in AD are similar to that in diabetes. Therefore, it is promising to find a new pathway to consider the research strategy on exploring the nootropics candidates rooting in herbal medicine and its formula.

Neuroprotective effects of cistanche

References

1 Dong YH, Mao XQ, Liu L, et al. Prevalence of dementia among Chinese people aged 60 years and over a meta-analysis. Chin J Public Health 2014, 30(4): 512-515.

2. Roberts RO, Knopman DS, Przybelski SA, et al. Association of type2 diabetes with brain atrophy and cognitive impairment. Neurol 2014, 82(13): 1132–1141.

3. Morris JK, Vidoni ED, Honea RA, et al. Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging 2014, 35(3): 585–589.

4. Cai H, Cong WN, Ji S, et al. Metabolic dysfunction in Alzheimer’s disease and related neurodegenerative disorders. Curr Alzheimer Res 2012, 9(1): 5-17.

5. Kop FD, Frolich L. Risk of incident Alzheimer’s disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis 2009, 16(4): 677–685.

6. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37: 1595–1607. 7. Mark Yarchoan, Steven E Arnold. Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease. Diabetes, 2014, 63(7): 2253-2261.

8. Mielke JG, Wang YT. Insulin, synaptic function, and opportunities for Neuroprotection．ProgMolBiolTranslSci 2011, 98: 133-186．

9. Zhang B, Sun L, Zhang Y, et al. Expression and Correlation of Sex Hormone-binding Globulin, Insulin Signal Transduction and Glucose Transporter Proteins in the Gestational Diabetes Mellitus Placental Tissue. J China Med Univ 2017, 46(2): 97-102.

10. Bondy CA, Cheng CM. Signaling by insulin-like growth factor 1 in the brain. Eur J Pharmacol 2004, 490(1-3): 25-31.

11. Scrima M, Marco CD, Fabiani F, et al.Signaling net-works associated with AKT activation in non-small cell lung cancer(NSCLC): New insights on the role of the phosphatidylinositol-3 kinase. PLoS One 2012, 7(2): e30427.

12. Sramek Jan, Vlasta NF, Kamila B, et al. p38 MAPK Is activated but does not play a key role during apoptosis induction by saturated fatty acid in human pancreatic β-Cells. Int J MolSci 2016, 17(2): 159.

13. Bosco D. Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. J Cell Mol Med 2011, 15: 1807-1821.

14. Dineley KT, Jahrling JB, Denner L. Insulin resistance in Alzheimer’s disease. Neurobiol Dis 2014, 72(Pt A): 92-103.

15. Ridler C. Alzheimer disease: misfolded diabetes-mellitus peptide seeds amyloid-β aggregation. Nat Rev Neurol 2017, 13(3):128.

16. Lutz TA. The role of amylin in the control of energy homeostasis.Am J PhysiolRegulIntegr Comp Physiol 2010, 298: R1475-R1484.

17. Lim YA, Ittner LM, Lim YL, et al. Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett 2008, 582(15): 2188-2194.

18. Fu W, Ruangkittisakul A, MacTavish D, et al. Amyloid-beta (Abeta) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J BiolChem 2012, 287(22): 18820-18830.

19. Shen Y, Joachimiak A, Rosner MR, et al. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. Nature 2006, 443(7113): 870-874.

20. Jackson K, Barisone GA, Diaz E, et al. Amylin deposition in the brain: The second amyloid in Alzheimer disease. Ann Neurol 2013, 74 (4): 517-526.

21. Zhang T, Zeng QH, Liu Y, et al. Distribution and expression of amylin in the brain of Alzheimer’s disease and normal mice. Journal of the third military medical university 2016, 38(3): 258-262.

22. PrashantNadkarni, Oleg G Chepurm, George G Holz. Regulation of Glucose Homeostasis by GLP-1. NIH Public Access 2014, 121: 23-65.

23. WU MJ, LU TT, WANG FJ, et al. The Role of GLP-1 for the Central Nervous System. Med Recapitulate 2016, 22(5): 886-889.

24. Dickson SL, Shirazi RH, Hansson C, et al. The glucagon-like peptide 1 (GLP-1) analog, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J Neurosci, 2012, 32(14): 4812-4820.

25. Li Y, Duffy KB, Ottinger MA, et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 2010, 19(4): 1205-1219.

26. Holscher C. Incretin analogs that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Pat CNS Drug Discov 2010, 5: 109-117.

27. Gault VA, Holscher. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 2008, 587: 112-117.

28. Tang J, Dong Q. Alzheimer’s disease and treatment progress of GLP-1 analogs. Chin J Clin Neurosci 2015, 23(1): 95-101.

29. Chase Romere, Clemens Duerrschmid, Juan Bournat, et al. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell 2016, 2(63): 1-14.

30. Bindlish S, Presswala LS, Schwartz F. Lipodystrophy: syn-drome of severe insulin resistance. Postgrad Med 2015, 127: 511-516.

31. Denis R. Palatability can drive feeding independent of AgRP neurons. Cell Metab 2015, 22: 646-657.

32. Zhu LJ, Liu MY, Li H, et al. The Different Roles of Glucocorticoids in the Hippocampus and Hypothalamus in Chronic Stress-Induced HPA Axis Hyperactivity. PLOS ONE 2014, 9(5): e97689.

33. Koper JW, Vanr OSSUM EF. Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids 2014, 92: 62-73.

34. Yu XJ, Li Y, Tai LW, et al. Glucocorticoid effects on adult hippocampal neural progenitor cells. Chin J Tissue EngRes 2013, 19(16): 3521-3526.

35. Hu WH, Lu GH, Xu H. Changes in serum cortisol levels in patients with Alzheimer's disease and mild cognitive impairment. Chin J gerontology 2016, 36(17): 4295-4297.

36. Yu X. The role of stress in the development of Alzheimer’s disease. World Latest Med Inf 2017, 17(21): 167-168.

37. Penguin Wang, Caixin Su, HuiliFeng, et al. Curcumin regulates insulin pathways and glucose metabolism in the brains of APP swe/PS1dE9 mice. Int J ImmunopatholPharmacol2017, 30(1): 25-43.

38. Durairajan SSK, Liu LF, Lu JH, et al.Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer’s disease transgenic mouse model. Neurobiol Aging 2012, 33: 2903-2919.

39. Sun BL, Chiang CK. Effect of dancing injection on apnea-hypopnea syndrome patients with Type 2 diabetes. Chin J Clin Rational Drug Use 2014; 7: 121–122.

40. Lin JY, Liu JH, Liu XH, et al. Effect of FufangDanshenDiwan on the cognitive function of diabetic patients complicated with coronary heart disease. Chin J New Drugs 2009, 18: 1213–1216.

41. Zheng S, Li BZ, Li NL, et al. ZiBuPiYin recipe prevents diabetes-associated cognitive decline in rats: possible involvement of ameliorating mitochondrial dysfunction, insulin resistance pathway and histopathological changes. BMC Complement Altern Med 2016, 16: 200.

42. SW Seto, GY Yang, A Bensoussan, et al. Diabetes Mellitus, Cognitive Impairment, and Traditional Chinese Medicine. Int J Endocrinol 2015: 810439.

43. Kleinridders A, Cai W, Cappellucci L, et al. Insulin resistance in the brain alters dopamine turnover and causes behavioral disorders. ProcNatlAcadSci USA 2015, 112: 3463-3468.